Sunday, October 10, 2010 5:12:48 PM
Doc Seymour:
I’ve been invited by the Ministers of Health of two West African countries to come over and start treating people whose viruses have grown resistant to the triple combination therapy. Now I’m just beginning to investigate the Compassionate Use Rules, to see whether we can do this. And as soon as we have production capability to make enough material to treat people and I get a clearance from the FDA to do this, I’m going to Africa. My goal is to treat these people who are now, the drugs aren’t working for HIV, and achieve the same results we’ve achieved in animals which we’ve reported have been extremely exciting and we describe what we’ve accomplished as creating a “functional cure”. That is eradicating the virus to the extent that it does not cause damage to the person anymore. Not necessarily getting rid of every last virus particle, but these people can live a normal life and it is as if they have a chronic disease. Now, that is one goal. I have a more ambitious goal having been in the HIV treatment arena for thirty years. I want to eradicate the virus completely. I think it is possible. We have to prove it and maybe I’ll be wrong, but on the other hand, that is my goal, to eradicate the virus completely. With diseases like Dengue, I think we can do that. Unfortunately in Dengue, there are 100 million cases of Dengue a year and a certain number of people when they get re-infected with the virus, develop a fatal disease called Dengue Hemorrhagic Fever and our results at University of California Berkeley have been quite good in animals who have been especially designed to show the symptoms of Dengue Hemorrhagic Fever. I’ve been invited by the Health Minister of a South American country to come down and treat people who would ordinarily die of Dengue Hemorrhagic Fever, sometime next year. We are going as quickly as we can to find the space to build a manufacturing capability so that I can go off and do those things.
Recent NNVC News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/27/2024 08:15:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:30:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 08:05:25 PM
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
Unitronix Corp. to Invest $3 Million in USA Unity Coin Project • UTRX • Oct 7, 2024 7:08 AM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM